Pharmasset, Inc. (VRUS): INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227
11/3/2009 8:26:55 AM
More...
|
Pharmasset, Inc. (VRUS) Nominates PSI-879 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development
10/6/2009 8:08:15 AM
More...
|
Pharmasset, Inc. (VRUS) Reports Fiscal Third Quarter 2009 Financial Results
8/11/2009 9:16:41 AM
More...
|
Pharmasset, Inc. (VRUS) Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
7/31/2009 9:19:45 AM
More...
|
Pharmasset, Inc. (VRUS) Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development
7/7/2009 8:58:10 AM
More...
|
Pharmasset, Inc. (VRUS) Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
6/9/2009 8:58:10 AM
More...
|
Pharmasset, Inc. (VRUS) Reports Fiscal Second Quarter 2009 Financial Results
5/12/2009 12:01:22 PM
More...
|
Roche (RHHBY) and Pharmasset, Inc. (VRUS) Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
4/27/2009 9:40:53 AM
More...
|
Roche (RHHBY), InterMune, Inc. (ITMN), And Pharmasset, Inc. (VRUS) Announce: Ground-Breaking Combination Of All-Oral Agents Demonstrates Potential As Hepatitis C Treatment Regimen
4/27/2009 9:07:56 AM
More...
|
InterMune, Inc. (ITMN) and Pharmasset, Inc. (VRUS) to Discuss INFORM-1 Results From EASL Conference, April 25
4/21/2009 9:51:21 AM
More...
|
|